TPST

Tempest TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.80

+113.7% vs current

Most likely

Base case

55%

Probability

Target price

$1.45

+10.7% vs current

B-

Bear case

25%

Probability

Target price

$0.60

-54.2% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

This is a filing-led, low-coverage biotech tape rather than a sentiment-driven one. The 6/2 warrant filing adds a near-term dilution/watch item, while the 5/14 business update keeps TPST-2003 clinically relevant; with no recent news flow, no social context, and no fresh analyst revisions, confidence should stay cautious.

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-02event6/2 warrant issuance adds dilution overhangHigh impact

Tempest's 6/2 8-K disclosed a New Warrant with a $1.73 exercise price, exercisable only after required Nasdaq stockholder approval, which keeps a financing and dilution overhang on the stock [#SEC-8K-2026-06-02].

2026-12-31catalystTPST-2003 data and manufacturing prep support registrational pathHigh impact

The 5/14 quarter update confirmed positive interim TPST-2003 data, a 100% complete response rate among CAR-T-naive efficacy-evaluable patients, no Grade >=3 CRS or ICANS in REDEEM-1, and AGCTC as lead manufacturing partner ahead of the planned U.S. registrational study later in 2026 [#SEC-8K-2026-05-14].

2027-12-31catalystPartnering and BD optionality expand longer-term upsideHigh impact

Tempest's March asset acquisition and May appointment of a Head of Business Development reinforce a partner-funded development model, including a China BLA plan for TPST-2003 in 2027 and broader licensing/transaction optionality [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology